/content/mofsl-website-adobe/fragments/open-demat-popup
style
hide-in-desktop

US Stock Details

Get in-depth insights on US stocks, including fundamentals, financials, shareholding, peer comparison, and performance. Track key metrics, price trends, and market sentiment for informed decisions. Stay ahead with expert analysis and data-driven strategies at Motilal Oswal.

style
pb-0

WEREWOLF THERAPEUTICS INC

us-stock
To Invest in {{usstockname}}
/content/mofsl-website-adobe/demat-form-fields
style
sticky-block,pt-0
us-stock
style
pt-0
$0.9179 0.0673(6.73%) HOWL at 04 Dec 2025 04:34 PM Biotechnology
Lowest Today 0.82
Highest Today 0.9229
Today’s Open 0.86
Prev. Close 0.86
52 Week High 2.38
52 Week Low 0.60
Day’s Range: Low 0.82 High 0.9229
52-Week Range: Low 0.60 High 2.38
1 day return -
1 Week return -10.67
1 month return -26.35
3 month return -33.17
6 month return -30.86
1 year return -49.59
3 year return -49.02
5 year return -
10 year return -

Institutional Holdings

RA Capital Management, LLC 14.61

Mpm Asset Management, LLC 9.42

MPM Oncology Impact Management LP 5.27

Bank of America Corp 4.66

Vanguard Group Inc 2.84

Vanguard Total Stock Mkt Idx Inv 1.92

Millennium Management LLC 1.52

Sphera Funds Management Ltd. 1.37

DC Funds, LP 1.29

Partner Fund Management LP 0.88

Jane Street Group LLC 0.82

BlackRock Inc 0.79

Geode Capital Management, LLC 0.72

Renaissance Technologies Corp 0.69

Vanguard Institutional Extnd Mkt Idx Tr 0.62

Alyeska Investment Group, L.P. 0.52

Goldman Sachs Group Inc 0.50

Fidelity Extended Market Index 0.36

State Street Corp 0.26

A4Investments SICAV SIF ACCI IlanaA2EURH 0.26

Marshall Wace Asset Management Ltd 0.23

Bridgeway Capital Management, LLC 0.22

Bridgeway Ultra-Small Company Market 0.22

AQR Capital Management LLC 0.20

Y-Intercept (Hong Kong) Ltd 0.18

Vifag 2002 SICAV 0.15

Fidelity Total Market Index 0.12

Extended Equity Market Fund K 0.12

Fidelity Series Total Market Index 0.09

Northern Trust Extended Eq Market Idx 0.09

NT Ext Equity Mkt Idx Fd - L 0.09

Spartan Extended Market Index Pool F 0.08

NT Col R2000 Val Idx Fd -DC -L -TierFour 0.06

NT Ext Equity Mkt Idx Fd - NL 0.05

NT Ext Equity Mkt Idx Fd - DC - NL - T2 0.04

Spartan Total Market Index Pool G 0.04

Fidelity Nasdaq Composite Index 0.03

State Street Russell 2000 Value CIT 0.03

NT Ext Eq Mkt Indx Fd DC Lending Tier 5 0.02

Vanguard U.S. Eq Idx £ Acc 0.02

Market Status

Strong Buy: 4

Buy: 2

Hold: 0

Sell: 0

Strong Sell: 0

Fundamentals

Market Cap 41.74 M

PB Ratio 1.6391

PE Ratio 0.0

Enterprise Value 20.13 M

Total Assets 126.93 M

Volume 624850

Company Financials

Annual Revenue FY23:25725000 25.7M, FY22:16401000 16.4M, FY21:0 0.0M, FY20:0 0.0M, FY19:0 0.0M

Annual Profit FY23:null 0.0M, FY22:16401000 16.4M, FY21:null 0.0M, FY20:null 0.0M, FY19:null 0.0M

Annual Net worth FY23:-37295000 -37.3M, FY22:-51564000 -51.6M, FY21:-49767000 -49.8M, FY20:-14939000 -14.9M, FY19:-10990000 -11.0M

Quarterly Revenue Q3/2025:0 0.0M, Q2/2025:0 0.0M, Q1/2025:0 0.0M, Q3/2024:0 0.0M, Q2/2024:1143000 1.1M

Quarterly Profit Q3/2025:null 0.0M, Q2/2025:-406000 -0.4M, Q1/2025:-426000 -0.4M, Q3/2024:null 0.0M, Q2/2024:689000 0.7M

Quarterly Net worth Q3/2025:-16370000 -16.4M, Q2/2025:-17982000 -18.0M, Q1/2025:-18089000 -18.1M, Q3/2024:-16673000 -16.7M, Q2/2024:-17249000 -17.2M

Fund house & investment objective

Company Information Werewolf Therapeutics, Inc., a biopharmaceutical company, engages in the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer and other immune-mediated conditions. The company designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies through its proprietary PREDATOR platform. Its lead product candidates are WTX-124, a conditionally activated Interleukin-2 INDUKINE molecule for the treatment of advanced or metastatic solid tumors; and WTX-330, a conditionally activated Interleukin-12 INDUKINE molecule for the treatment of advanced or metastatic solid tumors and lymphoma. The company is also developing JZP898, a conditionally activated interferon alpha INDUKINE molecule for the treatment of cancer; WTX-921, a conditionally activated IL-10 INDUKINE molecule for the treatment of inflammatory bowel disease and potentially other inflammatory diseases; and WTX-712, an activated Interleukin-21(IL-21) and WTX-518, an activated IL-18 (IL-18) INDUKINE molecule for the treatment of cancer. Werewolf Therapeutics, Inc. was incorporated in 2017 and is headquartered in Watertown, Massachusetts.

Organisation Biotechnology

Employees 39

Industry Biotechnology

CEO Dr. Daniel J. Hicklin Ph.D.

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right
style
align-center,button-arrow